Cellular proviral HIV-DNA decline and viral isolation in naive subjects with < 5000 copies/ml of HIV-RNA and > 500 x 106/l CD4 cells treated with highly active antiretroviral therapy

AIDS

Volumn 14, Issue 1, 2000, Pages 23-29

  Andreoni, Massimo ^a   Parisi, Saverio G ^c   Sarmati, Loredana ^a   Nicastri, Emanuele ^a   Ercoli, Lucia ^a   Mancino, Giorgio ^a   Sotgiu, Giovanni ^b   Mannazzu, Marco ^b   Trevenzoli, Marco ^c   Tridente, Giuseppe ^c   Concia, Ercole ^c   Aceti, Antonio ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

Early treatment of HIV infection; Highly active antiretroviral therapy; HIV isolation; Proviral HIV DNA

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; STAVUDINE; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; DNA DETERMINATION; DRUG SENSITIVITY; FEMALE; HALF LIFE TIME; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; NUCLEOTIDE SEQUENCE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROVIRUS; RETROSPECTIVE STUDY; T LYMPHOCYTE; VIREMIA; VIRUS DETECTION; VIRUS ISOLATION; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDANOSINE; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROVIRUSES; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; STAVUDINE; VIREMIA;

EID: 0033971567     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200001070-00003     Document Type: Article

References (22)

1. 1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-8-60.
2. 2. Arnò A, Ruiz L, Juan M, et al. Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years. AIDS 1998. 12:697-704.
3. 3. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999, 340:1614-1622.
4. 4. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999, 340:1605-1613.
5. 5. Finzi D, Bjankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999. 5:512-517.
6. 6. Harrigan PR, Whaley M, Montaner SC. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 1999, 13:F59-F62.
7. 7. Albert J, Fenyo EM. Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical specimens by polymerase chain reaction with nested primers. J Clin Microbiol 1990, 28:1560-1564.
8. 8. Di Stefano M, Sabri F, Leitner T, et al. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during Zidovudine treatment. ; Clin Microbiol 1995, 33: 352-355.
9. 9. Schimt JC, Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996, 10: 995-999.
10. 10. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995, 333:450-451.
11. 11. Deeks S, Volberding P. Antiretroviral therapy for HIV infection: promises and problems. JAMA 1998, 279:1343-1344.
12. 12. Cone RW, Gowland P, Opravil M, Grob P, Ledergerber B and the Swiss HIV Cohort Study. Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV-1 infection. AIDS 1998, 12:2253-2260.
13. 13. Izopet J, Salama G, Pasquier C, et al. Decay of HIV-DNA in patients receiving suppressive antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrov 1998, 19:478-483.
14. 14. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997, 276:960-964.
15. 15. Donovan RM, Bush CE, Smereck SM, Moore E, Cohen F, Saravolatz LD. Antiretroviral therapy is asociated with a decrease in unintegrated HIV-1 DNA in pediatrie patients. J Acquir Immune Defic Syndr 1994, 7:1237-1241.
16. 16. Zhang YM, Dawson SC, Landsman D, Lane HC, Salzman NP. Persistence of four related human immunodeficiency virus sub-types during the course of zidovudine therapy: relationship between virion RNA and proviral DNA. J Virol 1994, 68: 425-432.
17. 17. Chun T, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997. 387:183-188.
18. 18. Wong JK, Hezareh M, Gunthard HF, ef al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
19. 19. Gunthard HF, Wong JK, Ignacio CC, et al Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998. 72:2422-2248.
20. 20. Roeder M. Getting to the HAART of T cell dynamics. Nat Med 1998, 4:145-146.
21. 21. Emery S, Lane HC. Immune reconstitution in HIV infection. Curr Opin Immunol 1997, 9:568-572.
22. 22. Bisset LR, Cone RW, Huber W, et al. Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study. AIDS 1998,12:2115-2123.